New research article in The Lancet HIV>
Efficacy, safety, and tolerability of switching to long-acting #cabotegravir plus #rilpivirine versus continuing fixed-dose #bictegravir, #emtricitabine, and #tenofovir alafenamide in virologically suppressed adults with #HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial
https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(23)00136-4/fulltext
#cabotegravir #rilpivirine #bictegravir #emtricitabine #tenofovir #hiv
New research article in The Lancet HIV> Predicted effects of the introduction of long-acting injectable #cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(22)00365-4/fulltext #PrEP #HIV
The Tyee: A Promising New Way to Prevent HIV Infections (in News) https://thetyee.ca/News/2022/12/22/Promising-New-Way-To-Prevent-HIV-Infections/ #bcnews #TheTyee - via @tyee@mstdn.ca #Community-BasedResearchCentreVancouver #CanadianInstitutesofHealthResearch #MichaelMontessWesternUniversity #U.S.FoodandDrugAdministration #PublicHealthAgencyofCanada #Pre-exposureprophylaxis #TheFutureofPrEPisNow #CanadianHIVmedicine #ViiVHealthcare #cabotegravir #HealthCanada
#BCNews #TheTyee #community #CanadianInstitutesofHealthResearch #MichaelMontessWesternUniversity #U #PublicHealthAgencyofCanada #pre #TheFutureofPrEPisNow #CanadianHIVmedicine #ViiVHealthcare #cabotegravir #HealthCanada
The big news from Friday. The #HIV prevention injection has been approved in #SouthAfrica https://www.spotlightnsp.co.za/2022/12/01/first-hiv-prevention-injection-approved-in-sa/ It has since been confirmed by SAHPRA. Follows roughly a year after #FDA approval. Pilot projects in SA to start early 2023, but wider rollout will depend on pricing from #ViiV. #PrEP #CABLbA #Cabotegravir
#cabotegravir #cablba #prep #viiv #fda #southafrica #hiv
Long-acting injectable #antiretroviral medicines can help #prevent new #HIV infections: #AIDS campaigners are urging ViiV Healthcare to take vital next steps to enable access to #cabotegravir
⤵️
https://www.unaids.org/en/resources/presscentre/featurestories/2022/november/20221116_long-acting-injectable-HIV-medicines
#antiretroviral #prevent #HIV #aids #cabotegravir
New research article in The Lancet HIV> Relative cost-effectiveness of long-acting injectable #cabotegravir versus oral pre-exposure prophylaxis in #SouthAfrica based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(22)00251-X/fulltext#.Y2oNiXXhSkE.twitter #PrEP #HIV
#hiv #prep #southafrica #cabotegravir